Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Josep Brugada
Josep Brugada Terradellas (Spain)
Presentation webcastPresentation slides
List of Authors: Elena Arbelo, Gerhard Hindriks, Aldo Maggioni, John Morgan, Luigi Tavazzi, Panos Vardas, Josep Brugada
Aims: The Atrial Fibrillation Ablation Pilot Study is a prospective, multicentre, sentinel registry that has been designed to describe the clinical epidemiology of patients undergoing an atrial fibrillation (AFib) ablation procedure, and the diagnostic/therapeutic processes applied in these patients across Europe. Methods and results: A total of 74 Centres in 10 European countries were asked to enrol 20 consecutive patients undergoing a first AFib ablation procedure. Between October 2010 and May 2011, 1410 patients were included, of which 1391 underwent an AFib ablation (98.7%). The median age was 60 years (IQR 52–66), and 28% females. History of stroke was seen in 7% of patients. Two thirds presented paroxysmal AFib and 38% were diagnosed of lone AFib. Symptoms were present in 86% of cases. The indications for ablation were mostly symptomatic AFib, but in over a third of patients, there was also a desire for a drug-free lifestyle and the maintenance of sinus rhythm. The ablation was performed with an open irrigation in 78%. Complications occurred in 7.7%. Cardiac perforation was reported in 0.8% of patients and a cardioembolic event in 0.6%. The median duration of hospitalization was 3 days (IQR 2–4). At discharge, 91.4% of patients were in sinus rhythm, 87.4% of patients were given vitamin K antagonists and 67% antiarrhythmic medication. There was one cardiovascular death non-related to the ablation procedure. Conclusion: The Atrial Fibrillation Ablation Pilot Study provides relevant information with regards to the current clinical practice across Europe. These data may prove useful when designing management strategies of patients suffering from AFib.
Clinical Registry Highlight I - Risk and treatment reality
© 2017 European Society of Cardiology. All rights reserved